%PDF-1.4
%
1 0 obj
<<
/Author (zlom2)
/CreationDate (D:20221013154315+01'00')
/Creator (QuarkXPress\(R\) 18.6)
/ModDate (D:20221013161151+02'00')
/Producer (QuarkXPress\(R\) 18.6)
/Title ( S e s t a v a 1)
/XPressPrivate (%%DocumentProcessColors: Cyan Magenta Yellow Black\n%%EndComments)
>>
endobj
2 0 obj
<<
/Lang (en-US)
/MarkInfo <<
/Marked true
>>
/Metadata 3 0 R
/PageLabels 4 0 R
/Pages 5 0 R
/StructTreeRoot 6 0 R
/Type /Catalog
/ViewerPreferences <<
/DisplayDocTitle true
>>
/JT 7 0 R
/QXPr:DeviceNColorants 8 0 R
>>
endobj
3 0 obj
<<
/Length 3013
/Subtype /XML
/Type /Metadata
>>
stream
QuarkXPress(R) 18.6
2022-10-13T15:43:15+01:00
2022-10-13T16:11:51+02:00
QuarkXPress(R) 18.6
%%DocumentProcessColors: Cyan Magenta Yellow Black
%%EndComments
Sestava 1
zlom2
endstream
endobj
4 0 obj
<<
/Nums [0 9 0 R]
>>
endobj
5 0 obj
<<
/Count 1
/Kids [10 0 R]
/MediaBox [0 0 1417.323 797.244]
/Type /Pages
>>
endobj
6 0 obj
<<
/K 11 0 R
/ParentTree 12 0 R
/ParentTreeNextKey 2
/RoleMap <<
/Story /Sect
/Article /Art
/Endnote /Note
/Footnote /Note
>>
/Type /StructTreeRoot
>>
endobj
7 0 obj
<<
/A [13 0 R]
/V 1.1
/Cn [14 0 R]
>>
endobj
8 0 obj
<<
>>
endobj
9 0 obj
<<
/S /D
>>
endobj
10 0 obj
<<
/BleedBox [0 0 1417.323 797.244]
/Contents 15 0 R
/Parent 5 0 R
/Resources 16 0 R
/StructParents 1
/Tabs /S
/TrimBox [0 0 1417.323 797.244]
/Type /Page
/xb1 0
/xb2 1417.323
/xt1 0
/xt2 1417.323
/yb1 0
/yb2 797.244
/yt1 0
/yt2 797.244
/u2pMat [1 0 0 -1 0 797.244]
>>
endobj
11 0 obj
<<
/K 17 0 R
/Lang (en-US)
/P 6 0 R
/S /Document
>>
endobj
12 0 obj
<<
/Nums [1 18 0 R]
>>
endobj
13 0 obj
<<
/Dt (D:20221013154317)
/JTM (Distiller)
>>
endobj
14 0 obj
<<
/D [19 0 R]
/MS 20 0 R
/Type /JobTicketContents
>>
endobj
15 0 obj
<<
/Length 54654
>>
stream
/Artifact <>BDC
q
1 i
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
.83 .01 0 0 k
/GS1 gs
21.26 662.598 1374.799 113.386 re
f
EMC
/Artifact <>BDC
1 g
1258.583 706.535 124.859 56.693 re
f
EMC
/Figure <>BDC
Q
q
1 i
1268.365 754.132 282.796 -39.129 re
W n
1258.583 763.228 124.859 -56.693 re
W* n
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
.83 .01 0 0 k
/GS1 gs
q 1 0 0 1 1342.996 750.373 cm 0 0 m
0 -.9326 .7729 -1.5859 1.7433 -1.5859 c
2.7502 -1.5859 3.5266 -.9326 3.5266 0 c
3.5266 .5031 l
3.5266 1.4693 2.7502 2.0952 1.7433 2.0952 c
.7729 2.0952 0 1.4693 0 .5031 c
0 0 l
f
Q
Q
q
1 i
1268.365 754.132 282.79 -39.118 re
W n
1268.365 754.132 282.796 -39.129 re
W n
1258.583 763.228 124.859 -56.693 re
W* n
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
.83 .01 0 0 k
/GS1 gs
q 1 0 0 1 1280.784 726.71 cm 0 0 m
-.2725 .1927 -.542 .5796 -.542 1.0851 c
-.542 1.7814 .0396 2.3618 .7764 2.3618 c
1.0493 2.3618 1.3182 2.2849 1.5164 2.1285 c
3.5654 .7394 5.6958 0 7.8672 0 c
10.27 0 12.009 1.2347 12.009 3.1746 c
12.009 3.2542 l
12.009 5.267 9.6465 6.0395 7.0134 6.7755 c
3.8733 7.668 .3901 8.7543 .3901 12.432 c
.3901 12.512 l
.3901 15.958 3.2566 18.245 7.2046 18.245 c
9.3345 18.245 11.662 17.582 13.595 16.536 c
13.984 16.306 14.331 15.878 14.331 15.297 c
14.331 14.601 13.75 14.02 13.016 14.02 c
12.747 14.02 12.513 14.099 12.357 14.178 c
10.656 15.143 8.8313 15.723 7.1273 15.723 c
4.7664 15.723 3.2566 14.482 3.2566 12.819 c
3.2566 12.745 l
3.2566 10.847 5.7341 10.107 8.4089 9.2927 c
11.507 8.3644 14.835 7.1614 14.835 3.5648 c
14.835 3.488 l
14.835 -.3141 11.702 -2.5215 7.7078 -2.5215 c
5.0751 -2.5215 2.1714 -1.5496 0 0 c
37.694 7.7846 m
37.694 3.5648 34.674 .0756 30.337 .0756 c
26.112 .0756 22.938 3.5648 22.938 7.8619 c
22.938 7.9379 l
22.938 12.159 25.919 15.688 30.259 15.688 c
34.479 15.688 37.694 12.159 37.694 7.8619 c
37.694 7.7846 l
h
22.35 14.601 m
20.81 12.764 19.877 10.414 19.877 7.8619 c
19.877 7.7846 l
19.877 5.2361 20.802 2.9003 22.33 1.0797 c
19.723 -4.7275 13.916 -8.7957 7.1479 -8.7957 c
-2.0389 -8.7957 -9.51 -1.3231 -9.51 7.8619 c
-9.51 17.045 -2.0389 24.519 7.1479 24.519 c
13.932 24.519 19.757 20.432 22.35 14.601 c
40.752 7.8619 m
40.752 7.9379 l
40.752 13.595 36.343 18.319 30.337 18.319 c
28.171 18.319 26.23 17.681 24.613 16.631 c
21.388 23.023 14.782 27.423 7.1479 27.423 c
-3.6423 27.423 -12.419 18.649 -12.419 7.8619 c
-12.419 -2.9272 -3.6423 -11.706 7.1479 -11.706 c
14.769 -11.706 21.365 -7.3132 24.595 -.9456 c
26.193 -1.9762 28.117 -2.5969 30.259 -2.5969 c
36.3 -2.5969 40.752 2.2054 40.752 7.8619 c
f
Q
Q
q
1 i
1268.365 754.132 282.796 -39.129 re
W n
1258.583 763.228 124.859 -56.693 re
W* n
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
.83 .01 0 0 k
/GS1 gs
q 1 0 0 1 1328.003 729.883 cm 0 0 m
0 12.086 l
-1.6296 12.086 l
-2.3232 12.086 -2.944 12.706 -2.944 13.406 c
-2.944 14.138 -2.3232 14.72 -1.6296 14.72 c
0 14.72 l
0 19.444 l
0 20.258 .6182 20.954 1.4714 20.954 c
2.2836 20.954 2.9846 20.258 2.9846 19.444 c
2.9846 14.72 l
8.1724 14.72 l
8.906 14.72 9.5258 14.102 9.5258 13.406 c
9.5258 12.668 8.906 12.086 8.1724 12.086 c
2.9846 12.086 l
2.9846 .3896 l
2.9846 -2.0516 4.3379 -2.944 6.3503 -2.944 c
7.3994 -2.944 7.9384 -2.6697 8.1724 -2.6697 c
8.8673 -2.6697 9.4485 -3.2548 9.4485 -3.951 c
9.4485 -4.4902 9.1006 -4.9175 8.5947 -5.1104 c
7.7444 -5.4608 6.8175 -5.6536 5.6555 -5.6536 c
2.4385 -5.6536 0 -4.0649 0 0 c
f
Q
q 1 0 0 1 1343.266 743.289 cm 0 0 m
0 .8132 .6592 1.5094 1.4735 1.5094 c
2.3245 1.5094 2.9836 .8492 2.9836 0 c
2.9836 -17.393 l
2.9836 -18.242 2.3673 -18.906 1.5094 -18.906 c
.6592 -18.906 0 -18.242 0 -17.393 c
0 0 l
f
Q
q 1 0 0 1 1370.445 734.495 cm 0 0 m
0 -4.22 -3.0244 -7.7087 -7.3552 -7.7087 c
-11.578 -7.7087 -14.751 -4.22 -14.751 .0768 c
-14.751 .153 l
-14.751 4.3737 -11.774 7.9026 -7.4368 7.9026 c
-3.2136 7.9026 0 4.3737 0 .0768 c
0 0 l
h
3.0602 .0768 m
3.0602 .153 l
3.0602 5.8099 -1.3521 10.534 -7.3552 10.534 c
-13.397 10.534 -17.816 5.7335 -17.816 .0768 c
-17.816 0 l
-17.816 -5.6563 -13.438 -10.381 -7.4368 -10.381 c
-1.3943 -10.381 3.0602 -5.5795 3.0602 .0768 c
f
Q
EMC
/P <>BDC
Q
q
1 i
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
/GS1 gs
BT
/F2 1 Tf
11 0 0 11 355.2483 703.4048 Tm
1 g
-.0009 Tc
.0009 Tw
[(St)14.1(ephane Champiat)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 464.7642 706.9297 Tm
0 Tc
0 Tw
(1)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 467.5496 703.4048 Tm
-.0003 Tc
.0003 Tw
[(, Aur)14.7(elien Mar)24.7(abelle)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 578.3857 706.9297 Tm
0 Tc
0 Tw
(1)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 581.1708 703.4048 Tm
-.0004 Tc
.0004 Tw
[(, Diwak)9.6(ar Da)14.6(v)9.6(a)-.4(r)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 668.5219 706.9297 Tm
0 Tc
0 Tw
(2)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 672.6338 703.4048 Tm
-.0004 Tc
.0004 Tw
[(, Pet)14.6(er Gr)14.6(ell)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 738.601 706.9297 Tm
0 Tc
0 Tw
(3)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 742.6997 703.4048 Tm
[(, K)10(ais)10(sa Ouli)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 810.2947 706.9297 Tm
(1)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 813.0797 703.4048 Tm
[(, Anna P)10(a)5(trikidou)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 909.0219 706.9297 Tm
(1)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 911.8071 703.4048 Tm
[(, Andr)15(eu Schoenenber)10(ger)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 1054.3782 706.9297 Tm
(4)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 1058.9255 703.4048 Tm
(, )Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 1065.3716 703.4048 Tm
( )Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 383.5273 690.2048 Tm
[(L)10(enk)10(a P)10(alo)18(v)10(a)0( Jelink)10(o)18(v)10(a)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 513.1184 693.7297 Tm
(4)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 517.6657 690.2048 Tm
[(, Ir)15(ena A)10(dkins)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 593.5549 693.7297 Tm
(4)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 598.1023 690.2048 Tm
[(, Sascha T)10(illmanns)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 699.7423 693.7297 Tm
(5)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 703.9003 690.2048 Tm
[(, Joachim Kiemle-K)10(allee)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 837.8363 693.7297 Tm
(5)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 841.9943 690.2048 Tm
[(, Richar)10(d Sachse)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 933.5253 693.7297 Tm
(5)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 937.6836 690.2048 Tm
[(, Elena G)-10(arr)25(alda)]TJ
ET
EMC
/P <>BDC
BT
6.6 0 0 6.6 1026.1674 693.7297 Tm
(6)Tj
ET
EMC
/P <>BDC
BT
11 0 0 11 1030.5369 690.2048 Tm
(; )Tj
ET
EMC
/P <>BDC
BT
9 0 0 9 1037.0928 690.2048 Tm
( )Tj
ET
EMC
/P <>BDC
BT
4.8 0 0 4.8 57.7012 675.9548 Tm
(1)Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 59.727 673.4048 Tm
-.0002 Tc
.0002 Tw
[(Gus)5.8(ta)8.8(v)10.6(e)-.2( R)5.8(ous)5.8(sy)50.8(, DITEP)59.8(, V)11.8(illejuif)26.8(, Fr)14.8(anc)8.8(e; )]TJ
ET
EMC
/P <>BDC
BT
4.8 0 0 4.8 224.4246 675.9548 Tm
0 Tc
0 Tw
(2)Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 227.4153 673.4048 Tm
[(Univ)10.8(ersity of Pittsbur)6(gh Medical C)6(ent)9(er Hillman Canc)9(er C)6(ent)9(er)54(, Pittsbur)6(gh, USA; )]TJ
ET
EMC
/P <>BDC
BT
4.8 0 0 4.8 554.1608 675.9548 Tm
(3)Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 557.1415 673.4048 Tm
[(Masaryk Memorial Canc)9(er Ins)6(titut)9(e)6(,)0( Brno)12(, Cz)9(ech R)6(epublic; )]TJ
ET
EMC
/P <>BDC
BT
4.8 0 0 4.8 793.8136 675.9548 Tm
(4)Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 797.1207 673.4048 Tm
[(SO)18(TIO Biot)9(ech a.s., Pr)15(ague)6(, Cz)9(ech R)6(epublic; )]TJ
ET
EMC
/P <>BDC
BT
4.8 0 0 4.8 978.6087 675.9548 Tm
(5)Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 981.6328 673.4048 Tm
[(SO)18(TIO Biot)9(ech A)15(G, Basel, S)6(witz)9(erland; )]TJ
ET
EMC
/P <>BDC
BT
4.8 0 0 4.8 1140.1768 675.9548 Tm
(6)Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1143.3545 673.4048 Tm
[(V)27(all d'Hebr)9(on Ins)6(titut)9(e of Onc)9(ology)51(, Bar)9(c)9(elona, Spain)]TJ
ET
EMC
/Artifact <>BDC
.83 .01 0 0 k
21.26 635.669 445.039 19.843 re
f
EMC
/P <>BDC
BT
11.9988 0 0 12 206.9067 641.9905 Tm
1 g
[(Back)10(gr)15(ound)]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 21.2587 620.5826 Tm
1 .89 0 0 k
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 620.5826 Tm
-.0001 Tc
-.0007 Tw
[(SO)47.9(T101 \(INN: nanrilk)20.9(efusp alf)14.9(a\) is a fusion pr)21.9(ot)14.9(ein of IL)39.9(-)29.9(15 and the IL)39.9(-)29.9(15 r)21.9(e)-.1(c)14.9(ept)14.9(or )]TJ
ET
EMC
/P <>BDC
BT
/TT1 1 Tf
10 0 0 10 425.2071 620.5826 Tm
0 Tc
0 Tw
<0001>Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 432.1456 620.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 435.1381 620.5826 Tm
(sushi+)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 466.298 620.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 608.5826 Tm
(domain.)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 69.4024 608.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 596.5826 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 596.5826 Tm
.0098 Tc
.6667 Tw
[(SO)47.8(T101 w)15.8(as in)16.8(v)26.8(e)-.2(s)9.8(tigat)14.8(ed in the phase 1 dose-escalation s)9.8(tudy A)21.8(URELIO-0)9.8(3)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 466.298 596.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 584.5826 Tm
-.0001 Tc
.0001 Tw
[(\(NCT04234)19.9(113\) as monother)24.9(ap)20.9(y and in c)14.9(ombination with pembr)21.9(olizumab)9.9(.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 395.4028 584.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 572.5826 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 572.5826 Tm
-.0003 Tc
-.0422 Tw
[(In the c)14.7(ombination part of A)21.7(URELIO-0)9.7(3, 21 patients w)21.7(e)-.3(r)21.7(e)-.3( tr)21.7(eat)14.7(ed at SO)47.7(T101 dose le)23.7(v)26.7(els of)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 466.2978 572.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 560.5826 Tm
[(1.5 t)15(o)0( 12.)20(0 )]TJ
ET
EMC
/P <>BDC
BT
/TT2 1 Tf
10 0 0 10 80.2327 560.5826 Tm
()Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 86.4973 560.5826 Tm
[(g/k)21(g on da)17(y)17(s)0( 1, 2, 8, 9 plus pembr)22(olizumab 200 mg on da)17(y 1 e)24(v)27(ery 3 w)22(eeks.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 459.2075 560.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 548.5826 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 548.5826 Tm
-.0001 Tc
-.0243 Tw
[(Maximum activ)20.9(ation of NK c)14.9(ells w)15.9(as observ)26.9(ed alr)21.9(eady at lo)21.9(w dose le)23.9(v)26.9(els, maximum CD8)]TJ
ET
EMC
/P <>BDC
BT
6 0 0 6 462.548 551.7825 Tm
0 Tc
0 Tw
(+)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 466.298 548.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 536.5826 Tm
.0048 Tw
[(T)90(-)0(c)15(ell activ)21(ation w)16(as r)22(eached at doses fr)22(om 9 t)15(o)0( 12 )]TJ
ET
EMC
/P <>BDC
BT
/TT2 1 Tf
10 0 0 10 283.2534 536.5826 Tm
0 Tw
()Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 289.5181 536.5826 Tm
-.0002 Tc
.005 Tw
[(g/k)20.8(g SO)47.8(T101 with no r)21.8(ele)23.8(v)20.8(ant e)9.8(ect)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 466.2985 536.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 524.5826 Tm
[(on T)89(r)22(eg c)15(ells.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 94.5326 524.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 512.5826 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 512.5826 Tm
-.01 Tc
(12 )Tj
ET
EMC
/P <>BDC
BT
/TT2 1 Tf
10 0 0 10 41.8209 512.5826 Tm
0 Tc
()Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 47.9857 512.5826 Tm
-.0102 Tc
-.021 Tw
[(g/k)20.8(g SO)47.8(T101 w)15.8(as select)14.8(ed as the c)14.8(ombination RP2D)39.8(, same as f)9.8(or SO)47.8(T101 monother)24.8(ap)20.8(y)84.8(.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 466.1979 512.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 500.5826 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 500.5826 Tm
-.0003 Tc
.0663 Tw
[(SO)47.7(T101 in c)14.7(ombination with pembr)21.7(olizumab w)15.7(as w)21.7(ell t)14.7(oler)24.7(at)14.7(ed. AEs w)21.7(e)-.3(r)21.7(e)-.3( mainly gr)24.7(ade)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 466.298 500.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 488.5826 Tm
.0099 Tc
.4072 Tw
[(1/)19.9(2 and tr)24.9(ansient. T)15.9(her)21.9(e w)15.9(as no additiv)26.9(e t)14.9(o)29.9(xicity when c)14.9(ombining SO)47.9(T101 with)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 466.2982 488.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 473.4696 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 480.6408 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 487.8122 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.9834 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 502.1548 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 509.326 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 516.4971 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 523.6686 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 530.8397 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 538.0111 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 545.1823 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 552.3537 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 559.5249 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 566.6963 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 573.8674 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 581.0389 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 588.21 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 595.3812 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 602.5526 488.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 476.5826 Tm
[(pembr)22(olizumab)10(.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 110.0327 476.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 464.5826 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 464.5826 Tm
-.0002 Tc
.0397 Tw
[(SO)47.8(T101 in c)14.8(ombination with pembr)21.8(olizumab r)21.8(esult)14.8(ed in clinical benet in mos)9.8(t patients,)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 466.2982 464.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 452.5826 Tm
[(e)24(v)27(en in CPI-r)22(efr)25(act)15(ory tumors [1,2].)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 202.3727 452.5826 Tm
( )Tj
ET
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 21.2587 426.4094 Tm
-.0001 Tc
.0001 Tw
[(A)14.9(URELIO-0)9.9(3 phase 1 int)14.9(erim ecacy of SO)29.9(T101 in c)14.9(ombination with pembr)14.9(olizumab)]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 21.2587 103.2599 Tm
-.0362 Tw
[(Clinical benet* w)15.9(as r)21.9(eport)14.9(ed in 15 out of 19 patients with at leas)9.9(t one pos)9.9(t-baseline tumor)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 466.2978 103.2599 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 91.2599 Tm
[(as)10(ses)10(sment:)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 80.8685 91.2599 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 79.2599 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 79.2599 Tm
[(1 c)15(onrmed CR)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 104.5627 79.2599 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 67.2599 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 67.2599 Tm
[(4 PRs; 3 PRs c)15(onrmed)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 145.5427 67.2599 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 55.2599 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 29.7626 55.2599 Tm
(10 SD; 9 SD )Tj
ET
EMC
/P <>BDC
BT
/TT3 1 Tf
10 0 0 10 89.9526 55.2599 Tm
<0003>Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 94.44 55.2599 Tm
[(2 or mor)22(e as)10(ses)10(sments)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 210.5421 55.2599 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 273.5421 55.2599 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 21.2587 35.2279 Tm
-.0001 Tc
.0001 Tw
[(* C)9.9(onsider)21.9(ed as at leas)9.9(t one oc)14.9(curr)21.9(enc)14.9(e of SD or r)21.9(esponse)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 951.0235 33.811 Tm
[(T)15.9(his s)9.9(tudy is in c)14.9(ollabor)24.9(ation with Mer)21.9(ck Sharp & Dohme LL)39.9(C, )]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1258.0134 33.811 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 951.0235 21.811 Tm
[(a subsidiary of Mer)22(ck & C)10(o)20(., Inc., Rah)12(w)16(a)17(y)85(,)0( NJ)15(, US)12(A.)]TJ
ET
EMC
/P <>BDC
BT
/F3 1 Tf
10 0 0 10 296.8981 21.055 Tm
-.0002 Tc
.0002 Tw
[( Da)9.8(ta present)9.8(ed a)9.8(t)-.2( A)9.8(S)14.8(C)23.8(O)-.2( 20)9.8(22 [2])]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 486.1407 620.5826 Tm
0 Tc
0 Tw
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 620.5826 Tm
.0008 Tc
.0742 Tw
[(A)22(URELIO-04 \(NCT05)10(256)10(381\) is a phase 2, open-label, single-arm, multic)15(ent)15(er s)10(tudy of)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 931.1813 620.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 608.5826 Tm
-.0056 Tc
-.0394 Tw
[(SO)47.7(T101 in c)14.7(ombination with pembr)21.7(olizumab t)14.7(o)-.3( e)23.7(v)]TJ
24.0099 0 TD
-.0057 Tc
-.0393 Tw
[(aluat)14.6(e)-.4( the ecacy and saf)9.6(ety in patients)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 931.1773 608.5826 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 596.5826 Tm
-.0001 Tc
.0001 Tw
[(with the f)9.9(ollo)21.9(wing select)14.9(ed adv)20.9(anc)14.9(ed solid tumor indications:)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 486.1407 335.0393 Tm
0 Tc
0 Tw
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 335.0393 Tm
-.0038 Tc
-.0412 Tw
[(Solid tumor selection is based on pr)21.9(e)23.9(vious pembr)21.9(olizumab s)9.9(tudies and/)79.9(or data with other)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 931.1792 335.0393 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 323.0393 Tm
[(CPIs and includes both CPI-r)22(elapsed and/)80(or CPI-nav)27(e tumors.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 801.8646 323.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 486.1407 311.0393 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 311.0393 Tm
.0099 Tc
.0956 Tw
[(A t)14.9(otal of up t)14.9(o)-.1( appr)21.9(o)29.9(ximat)14.9(ely 320 patients will be included, maximum 50 t)14.9(o)-.1( 5)29.9(7)-.1( per)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 931.1799 311.0393 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 935.2348 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 939.2897 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 943.3447 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 947.3996 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 951.4545 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 955.5094 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5641 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 963.619 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 967.674 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 971.7289 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 975.7838 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 979.8387 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 983.8937 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 987.9485 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 992.0035 311.0393 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 299.0393 Tm
-.0005 Tc
(indication.)Tj
ET
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 486.1407 93.131 Tm
0 Tc
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 93.131 Tm
[(Primary objectiv)18(e)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 584.2346 93.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 503.1483 81.131 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 508.6526 81.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6526 81.131 Tm
.0064 Tc
.0686 Tw
[(T)126.7(o)-.3( es)9.7(timat)14.7(e)-.3( the anti-tumor ecacy of SO)47.7(T101 in c)14.7(ombination with pembr)21.7(olizumab)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 931.179 81.131 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 934.929 81.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 938.679 81.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 942.429 81.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 946.179 81.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 949.929 81.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 953.679 81.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 957.429 81.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6526 69.131 Tm
.0099 Tc
.1568 Tw
[(ac)14.9(c)14.9(o)-.1(r)20.9(ding t)14.9(o)-.1( RECIS)14.9(T 1.)49.9(1 b)20.9(y)-.1( means of ORR, f)9.9(or each indication or disease c)14.9(ohort)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 931.1804 69.131 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 935.8477 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 940.515 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 945.1826 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 949.8497 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 954.5173 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.1846 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 963.852 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 968.5195 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 973.1869 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 977.8542 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 982.5216 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 987.1892 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 991.8563 69.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6526 57.131 Tm
-.001 Tc
[(separ)24(at)14(ely)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 562.8324 57.131 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 486.1407 45.131 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 494.6445 45.131 Tm
-.0017 Tc
(Status)Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 526.4145 45.131 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 503.1483 33.131 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 508.6526 33.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6526 33.131 Tm
-.0003 Tc
.0003 Tw
[(T)15.7(he s)9.7(tudy will enr)21.7(oll patients in Eur)21.7(ope and in the Unit)14.7(ed Stat)14.7(es.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 829.0925 33.131 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 503.1483 21.131 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 508.6526 21.131 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6526 21.131 Tm
[(FPI w)16(as in June 20)10(22.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 951.0223 620.5826 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 620.5826 Tm
-.0001 Tc
.0001 Tw
[(ORR ac)14.9(c)14.9(o)-.1(r)20.9(ding t)14.9(o)-.1( RECIS)14.9(T 1.)49.9(1 in patients with measur)24.9(able disease)]TJ
ET
EMC
/Artifact <>BDC
.83 .01 0 0 k
951.023 635.669 445.04 19.843 re
f
EMC
/P <>BDC
BT
/F2 1 Tf
12 0 0 12 1120.599 641.9905 Tm
1 g
0 Tc
0 Tw
(Primary endpoint)Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 951.0223 572.3936 Tm
1 .89 0 0 k
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 572.3936 Tm
-.0027 Tc
-.0423 Tw
[(T)85.8(ype)9.8(, fr)21.8(equency)84.8(,)-.2( and se)23.8(v)26.8(erity of TEAEs; AEs of special int)14.8(er)21.8(es)9.8(t; saf)9.8(ety labor)24.8(at)14.8(ory ndings;)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1396.059 572.3936 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 560.3936 Tm
[(vital signs; EC)20(G ndings)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1078.6365 560.3936 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 951.0223 548.3936 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 548.3936 Tm
-.0001 Tc
.0001 Tw
[(A)20.9(dditional ecacy endpoints:)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1107.8962 548.3936 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 968.0304 536.3936 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 973.5343 536.3936 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 976.5343 536.3936 Tm
-.0001 Tc
.0001 Tw
[(iORR in patients with measur)24.9(able disease ac)14.9(c)14.9(o)-.1(r)20.9(ding t)14.9(o)-.1( iRECIS)14.9(T)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1289.6841 536.3936 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 968.0304 524.3936 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 973.5343 524.3936 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 976.5343 524.3936 Tm
-.0056 Tc
-.0444 Tw
[(\(i\)BOR, \(i\)T)41.9(tR in patients with measur)24.9(able disease ac)14.9(c)14.9(o)-.1(r)20.9(ding t)14.9(o)-.1( RECIS)14.9(T 1.)49.9(1 and iRECIS)14.9(T)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1396.0129 524.3936 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 968.0304 512.3936 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 973.5343 512.3936 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 976.5343 512.3936 Tm
.01 Tc
.1908 Tw
[(\(i\)DoR, \(i\)CBR, \(i\)PFS ac)15(c)15(o)0(r)21(ding t)15(o)0( )]TJ
18.958 0 TD
0 Tc
0 Tw
( )Tj
T*
.01 Tc
.1908 Tw
[(RECIS)15(T 1.)50(1 and iRECIS)15(T and f)10(or mCRPC per)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1396.0623 512.3936 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 976.5343 500.3936 Tm
[(PCW)31(G3-modied RECIS)15(T 1.)50(1)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1115.5144 500.3936 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 968.0304 488.3936 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 973.5343 488.3936 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 976.5343 488.3936 Tm
-.0096 Tc
-.0404 Tw
[(mCRPC only: CT)48(C c)15(ount c)15(o)0(n)17(v)27(ersion, c)15(onrmed PS)12(A decline of )]TJ
ET
EMC
/P <>BDC
BT
/TT3 1 Tf
10 0 0 10 1278.6873 488.3936 Tm
0 Tc
0 Tw
<0003>Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 1283.0785 488.3936 Tm
-.0096 Tc
-.0404 Tw
[(50%, time t)15(o)0( c)15(onrmed)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1396.0121 488.3936 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 976.5343 476.3936 Tm
[(PS)12(A pr)22(ogr)22(es)10(sion)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1058.7643 476.3936 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 951.0223 464.3936 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 464.3936 Tm
-.0003 Tc
.0003 Tw
[(Plasma c)14.7(onc)14.7(entr)24.7(ations of SO)47.7(T101 o)26.7(v)26.7(er time)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1172.6963 464.3936 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 951.0223 452.3936 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 452.3936 Tm
-.0001 Tc
.0001 Tw
[(Incidenc)14.9(e)9.9(,)-.1( tit)14.9(er)89.9(, and time c)14.9(ourse of anti-drug antibodies agains)9.9(t SO)47.9(T101)]TJ
ET
EMC
/Artifact <>BDC
.83 .01 0 0 k
951.023 587.48 445.04 19.843 re
f
EMC
/P <>BDC
BT
/F2 1 Tf
12 0 0 12 1108.989 593.8015 Tm
1 g
0 Tc
0 Tw
[(Sec)15(ondary endpoints)]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 951.0223 405.1495 Tm
1 .89 0 0 k
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 405.1495 Tm
-.0072 Tc
-.0378 Tw
[(Changes in the e)26(xpr)22(es)10(sion of immune biomark)21(ers as c)15(ompar)22(ed t)15(o)0( baseline in tumor tis)10(sue;)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1396.0594 405.1495 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 393.1495 Tm
-.0165 Tc
-.0385 Tw
[(cir)21.9(culating tumor DNA fr)24.9(action \(mCRPC only\); s)9.9(t)-.1(a)5(tus of immune)10(, molecular)90(, disease-r)21.9(e)-.1(la)5(t)14.9(e)-.1(d,)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1395.9624 393.1495 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 381.1495 Tm
.0031 Tc
.0719 Tw
[(and other e)25.9(xplor)24.9(at)14.9(ory biomark)20.9(ers in blood and ar)21.9(chiv)20.9(al and/)79.9(or fr)21.9(eshly obtained tumor)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1396.0613 381.1495 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 369.1495 Tm
[(tis)10(sue)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 988.1363 369.1495 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 951.0223 357.1495 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 357.1495 Tm
[(Ov)27(er)25(all surviv)21(al)]TJ
ET
EMC
/Artifact <>BDC
.83 .01 0 0 k
951.023 420.236 445.04 19.843 re
f
EMC
/P <>BDC
BT
/F2 1 Tf
12 0 0 12 1105.5929 426.5574 Tm
1 g
-.0005 Tc
.0005 Tw
[(Explor)24.5(at)14.5(ory endpoints)]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 951.0223 311.6062 Tm
1 .89 0 0 k
0 Tc
0 Tw
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 311.6062 Tm
.0099 Tc
.2037 Tw
[(No f)9.9(ormal t)14.9(e)-.1(s)9.9(ting of s)9.9(t)-.1(atis)9.9(tical h)11.9(ypotheses is planned, analy)16.9(ses will be descriptiv)26.9(e)9.9(.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1396.0618 311.6062 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 1401.1974 311.6062 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 1406.333 311.6062 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 1411.4691 311.6062 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 1416.6047 311.6062 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 299.6062 Tm
-.0002 Tc
-.0447 Tw
[(C)9.8(onsidering benchmark ORRs, a futility analy)16.8(sis is planned f)9.8(or each indication separ)24.8(at)14.8(ely)84.8(.)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 1396.0618 299.6062 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.5266 287.6062 Tm
-.0002 Tc
.0002 Tw
[(Explor)24.8(at)14.8(ory analy)16.8(ses include immune and molecular biomark)20.8(ers.)]TJ
ET
EMC
/Artifact <>BDC
.83 .01 0 0 k
951.023 326.693 445.04 19.842 re
f
EMC
/P <>BDC
BT
/F2 1 Tf
12 0 0 12 1145.7268 333.0142 Tm
1 g
-.001 Tc
0 Tw
[(Statis)9(tics)]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
8 0 0 8 951.0223 242.3401 Tm
1 .89 0 0 k
-.0002 Tc
.025 Tw
[(1. Champiat S, et al: SO)47.8(T101, an IL)39.8(-2/IL)39.8(-)29.8(15 R)]TJ
ET
EMC
/P <>BDC
BT
/TT1 1 Tf
8 0 0 8 1121.0288 242.3401 Tm
0 Tc
0 Tw
<00020003>Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
8 0 0 8 1130.3256 242.3401 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1132.9243 242.3401 Tm
.0248 Tw
[(super)50.1(agonis)20(t, in c)30.1(ombina)10.1(tion with pembr)44.2(olizumab in pa)10.1(tients with)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0618 242.3401 Tm
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 959.5266 232.8402 Tm
-.002 Tc
-.043 Tw
[(adv)42(anc)30.2(ed solid tumors: Int)30.2(erim saf)20(ety and ecac)8.1(y r)44.2(esults fr)44.2(om the A)44.2(URELIO-0)20(3 dose escala)10.1(tion trial. Pr)44.2(esent)30.2(ed)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0637 232.8402 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 959.5266 223.3402 Tm
[(a)10.1(t: American As)20(socia)10.1(tion f)20(or Canc)30.1(er R)20(esear)44.2(ch Annual Meeting 20)20(22; April 8-)60(13, 20)20(22; Ne)44.2(w Orleans, LA.)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1365.4392 223.3402 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 213.8401 Tm
-.0001 Tc
-.0318 Tw
[(2. G)-10.1(arr)24.9(alda E, et al. , et al. Int)14.9(erim saf)9.9(ety and ecacy r)21.9(esults fr)21.9(om A)21.9(URELIO-0)9.9(3, a phase 1 dose escalation s)9.9(tudy of)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0618 213.8401 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 959.5266 204.3402 Tm
.0561 Tw
[(the IL)40(-2/IL)40(-)30(15R )]TJ
ET
EMC
/P <>BDC
BT
/TT1 1 Tf
8 0 0 8 1020.7278 204.3402 Tm
0 Tw
<00020003>Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
8 0 0 8 1030.0245 204.3402 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1032.8733 204.3402 Tm
.0561 Tw
[(r)44.2(e)0(c)30.1(ept)30.2(or super)50.1(agonis)20(t SO)96.1(T10)10.1(1 as a single agent and in c)30.1(ombina)10.1(tion with pembr)44.2(olizumab in)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0623 204.3402 Tm
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 959.5266 194.8402 Tm
-.003 Tc
-.042 Tw
[(pa)10.1(tients with adv)42(anc)30.1(ed solid tumors. Pr)44.2(esent)30.1(ed a)10.1(t: American Society of Clinical Onc)30.1(ology Annual Meeting 20)20(22;)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0603 194.8402 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 959.5266 185.3401 Tm
[(June 3-)80(7)200.1(,)0( 20)20(22; Chicago)40(, IL.)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 167.2221 Tm
.0054 Tc
.0696 Tw
[(Abbr)21.9(e)24(viations: AE, adv)27(e)-.1(rse e)24(v)26.9(ent; ALK, anaplas)9.9(tic lymphoma kinase; BOR, bes)9.9(t)0( o)26.9(v)26.9(e)-.1(r)24.9(a)-.1(ll r)21.9(e)0(sponse; CBR, clinical)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0608 167.2221 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1399.0608 167.2221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 157.722 Tm
.0488 Tw
[(benet r)25(a)5(t)15(e; CPD)40(, c)15(onrmed pr)22(ogr)22(es)10(siv)27(e disease; CPI, immune checkpoint inhibit)15(or; CT)48(C, cir)22(culating tumor c)15(ell;)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0623 157.722 Tm
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 148.2221 Tm
.007 Tc
.068 Tw
[(CR, c)14.9(omplet)14.9(e r)21.9(e)0(sponse; DoR, dur)24.9(ation of r)21.9(esponse; EC)19.9(G, electr)21.9(ocar)20.9(diogr)24.9(aph)11.9(y)-.1(; EC)19.9(OG PS, Eas)9.9(t)14.9(ern C)9.9(ooper)24.9(ativ)26.9(e)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0618 148.2221 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1399.0618 148.2221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1402.0618 148.2221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1405.0618 148.2221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1408.0618 148.2221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 138.7221 Tm
-.0001 Tc
-.0399 Tw
[(Onc)14.9(ology Gr)21.9(oup perf)9.9(ormanc)14.9(e s)9.9(t)-.1(atus; eCRF)99.9(, electr)21.9(onic case r)21.9(eport f)9.9(orm; EGFR, epidermal gr)21.9(o)21.9(wth f)14.9(act)14.9(or r)21.9(e)-.1(c)14.9(ept)14.9(or;)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0618 138.7221 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 129.222 Tm
-.0001 Tc
.0118 Tw
[(FPI, rs)9.9(t patient in; IL, int)14.9(erleukin; INN, int)14.9(ernational nonpr)21.9(oprietary name; iRECIS)14.9(T)99.9(,)-.1( R)9.9(esponse E)9.9(v)20.9(aluation Crit)14.9(eria)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0623 129.222 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 119.7221 Tm
-.0072 Tc
-.0378 Tw
[(In Solid T)85.9(umors f)9.9(or immune-based ther)24.9(apeutics; i.)84.9(v)84.9(., intr)24.9(a)18.9(v)26.9(enously; mCRPC, metas)9.9(tatic cas)9.9(tr)24.9(ation-r)21.9(esis)9.9(tant pr)21.9(os)9.9(tat)14.9(e)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0627 119.7221 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 110.2221 Tm
-.0001 Tc
.0673 Tw
[(canc)14.9(er; MSI-H/)69.9(dMMR, micr)21.9(osat)14.9(ellit)14.9(e ins)9.9(tability)14.9(-high/)49.9(mismat)14.9(ch r)21.9(epair decient; NK, natur)24.9(al killer; ORR, objectiv)26.9(e)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1396.0618 110.2221 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 100.722 Tm
-.0048 Tc
-.0402 Tw
[(r)21.9(esponse r)24.9(a)5(t)15(e)0(; PCW)30.9(G)0(, Pr)21.9(os)10(tat)15(e)-.1( Canc)14.9(er Clinical T)88.9(r)0(ials W)59.9(o)-.1(rking Gr)21.9(oup; PD)39.9(, pr)21.9(ogr)21.9(es)10(siv)27(e)-.1( disease;)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1312.9327 100.722 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 91.2221 Tm
-.0001 Tc
.0101 Tw
[(PFS, pr)21.9(ogr)21.9(es)9.9(sion-fr)21.9(ee surviv)20.9(al; PR, partial r)21.9(esponse; PS)11.9(A, pr)21.9(os)9.9(tat)14.9(e-specic antigen; RECIS)14.9(T)99.9(,)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1312.9336 91.2221 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 81.7221 Tm
.0099 Tc
.1814 Tw
[(R)9.9(esponse E)9.9(v)20.9(aluation Crit)14.9(eria In Solid T)85.9(umors; RP2D)39.9(, r)21.9(e)-.1(c)14.9(ommended phase 2 dose; s.)19.9(c.,)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1312.9336 81.7221 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1316.8645 81.7221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1320.795 81.7221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1324.7256 81.7221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1328.6565 81.7221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1332.5869 81.7221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1336.5178 81.7221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 1340.4484 81.7221 Tm
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 72.222 Tm
-.0151 Tc
-.0379 Tw
[(subcutaneously; SC)19.9(C, squamous c)14.9(ell car)21.9(cinoma; SD)39.9(, s)9.9(table disease; TEAE, tr)21.9(eatment-emer)20.9(gent)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1312.8137 72.222 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 62.7221 Tm
-.0001 Tc
.0182 Tw
[(adv)26.9(erse e)23.9(v)26.9(ent; T)88.9(r)21.9(eg, r)21.9(egulat)14.9(ory T c)14.9(ell; T)41.9(tR, time t)14.9(o)-.1( r)21.9(esponse; UPD)39.9(, unc)14.9(onrmed pr)21.9(ogr)21.9(es)9.9(siv)26.9(e)]TJ
ET
EMC
/P <>BDC
BT
8 0 0 8 1312.9341 62.7221 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
8 0 0 8 951.0223 53.2221 Tm
(disease)Tj
ET
EMC
/Artifact <>BDC
.83 .01 0 0 k
951.023 255.827 445.04 19.842 re
f
EMC
/P <>BDC
BT
/F2 1 Tf
12 0 0 12 1139.8173 262.1479 Tm
1 g
[(R)10(e)0(f)10(e)0(r)15(enc)15(es)]TJ
ET
EMC
/Artifact <>BDC
.83 .01 0 0 k
486.141 635.669 445.04 19.843 re
f
EMC
/P <>BDC
BT
12 0 0 12 668.9168 641.9905 Tm
1 g
-.0004 Tc
.0004 Tw
(Study design)Tj
ET
EMC
/Artifact <>BDC
1 G
0 J 0 j 3 w 10 M [] 0 d
35.516 761.728 121.724 -53.693 re
748.405 641.99 m
S
EMC
/P <>BDC
BT
17 0 0 17 68.7525 739.2819 Tm
-.001 Tc
0 Tw
[(Pos)9(t)14(er )]TJ
ET
EMC
/P <>BDC
BT
17 0 0 17 129.1027 739.2819 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
17 0 0 17 68.7525 720.2819 Tm
[(nr)90(. 7)-10(1)0(6)]TJ
ET
EMC
/P <>BDC
BT
20 0 0 20 189.6394 747.2283 Tm
-.005 Tc
[(A)15(URELIO-04: A phase 2, open-label, single-arm, multic)15(ent)15(er s)10(tudy t)15(o)0( det)15(ermine the ecacy and saf)10(ety )]TJ
ET
EMC
/P <>BDC
BT
20 0 0 20 1232.2247 747.2283 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
20 0 0 20 230.1195 723.2283 Tm
-.0052 Tc
.0002 Tw
[(of SO)29.8(T101 in c)14.8(ombination with pembr)14.8(olizumab in patients with select)14.8(ed adv)9.8(anc)14.8(ed solid tumors)]TJ
ET
EMC
/Artifact <>BDC
1312.934 15.444 83.128 88.411 re
f
EMC
/Figure <>BDC
Q
q
1 i
1326.945 90.856 69.449 -69.951 re
W* n
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
/GS1 gs
q
72.868 0 0 72.868 1325.033 19.815 cm
/Im1 Do
Q
EMC
/P <>BDC
Q
q
1 i
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
/GS1 gs
BT
/F1 1 Tf
7 0 0 7 1326.0168 95.0299 Tm
1 .89 0 0 k
-.03 Tc
0 Tw
[(Do)22(wnload the pos)10(t)15(er:)]TJ
ET
EMC
/Artifact <>BDC
.066 .001 0 0 k
486.142 364.213 445.039 212.598 re
f
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 503.1492 551.8032 Tm
1 .89 0 0 k
0 Tc
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6533 551.8032 Tm
[(Non-small c)15(ell lung canc)15(er)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 645.6732 551.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 520.1571 539.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.7111 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 539.8032 Tm
(2)Tj
ET
EMC
/P <>BDC
BT
6 0 0 6 534.7013 543.0031 Tm
.0084 Tc
(nd)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 542.4813 539.8032 Tm
.005 Tc
.138 Tw
[( or 3)]TJ
ET
EMC
/P <>BDC
BT
6 0 0 6 568.1323 543.0031 Tm
-.0266 Tc
0 Tw
(rd)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 574.4365 539.8032 Tm
.0049 Tc
.1381 Tw
[( line with disease pr)21.9(ogr)21.9(es)9.9(sion on or aft)14.9(er a CPI- and/)79.9(or platinum-)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 914.123 539.8032 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 918.5534 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 922.9835 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 927.4139 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 931.8444 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 936.2745 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 940.7051 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 945.1355 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 949.5659 539.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 527.8032 Tm
-.005 Tc
[(c)15(ontaining)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 580.3915 527.8032 Tm
-.0001 Tc
.0001 Tw
[( r)21.9(egimen, with no EGFR or ALK genomic tumor aberr)24.9(ations)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 873.9516 527.8032 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 503.1492 515.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6533 515.8032 Tm
[(C)10(olor)15(ectal canc)15(er)]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 600.9232 515.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 520.1571 503.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.6612 503.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 503.8032 Tm
(1)Tj
ET
EMC
/P <>BDC
BT
6 0 0 6 532.241 507.0031 Tm
-.0167 Tc
(st)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 537.5532 503.8032 Tm
-.0001 Tc
.0001 Tw
[( line with unr)21.9(esectable or metas)9.9(tatic MSI-H/)69.9(dMMR c)14.9(olor)21.9(ectal canc)14.9(er)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 874.3135 503.8032 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 503.1492 491.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6533 491.8032 Tm
[(Cutaneous SC)20(C)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 589.5434 491.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 520.1571 479.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.6612 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 479.8032 Tm
(1)Tj
ET
EMC
/P <>BDC
BT
6 0 0 6 532.2567 483.0031 Tm
-.0141 Tc
(st)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 537.6 479.8032 Tm
.0015 Tc
.0735 Tw
[( line with r)21.9(ecurr)21.9(ent or metas)9.9(tatic cutaneous SC)19.9(C or 2)]TJ
ET
EMC
/P <>BDC
BT
6 0 0 6 808.0549 483.0031 Tm
.0026 Tc
0 Tw
(nd)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 815.7661 479.8032 Tm
.0016 Tc
.0734 Tw
[( line if r)22(efr)25(act)15(ory or)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 914.1708 479.8032 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 917.9208 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 921.6708 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 925.4208 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 929.1708 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 932.9208 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 936.6708 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 940.4208 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 944.1708 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 947.9208 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 951.6708 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 955.4208 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.1708 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 962.9208 479.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 467.8032 Tm
[(r)22(elapsed aft)15(er a CPI-c)15(ontaining r)22(egimen)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 726.011 467.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 503.1492 455.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6533 455.8032 Tm
-.0002 Tc
.0002 Tw
[(Hepat)14.8(o)-.2(c)14.8(ellular car)14.8(cinoma)]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 641.4036 455.8032 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 520.1571 443.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.6612 443.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 443.8032 Tm
(2)Tj
ET
EMC
/P <>BDC
BT
6 0 0 6 534.6514 447.003 Tm
(nd)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 542.3311 443.8032 Tm
-.0001 Tc
.0001 Tw
[( or lat)14.9(er line aft)14.9(er pr)21.9(ogr)21.9(es)9.9(sion on or aft)14.9(er a CPI-c)14.9(ontaining r)21.9(egimen)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 873.2914 443.8032 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 503.1492 431.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6533 431.8032 Tm
(mCRPC)Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 549.8234 431.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 520.1571 419.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.6612 419.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 419.8032 Tm
(2)Tj
ET
EMC
/P <>BDC
BT
6 0 0 6 534.6514 423.003 Tm
(nd)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 542.3311 419.8032 Tm
-.0001 Tc
.0001 Tw
[( or lat)14.9(er line aft)14.9(er r)21.9(ecurr)21.9(enc)14.9(e or f)14.9(ailur)21.9(e of doc)14.9(etax)29.9(el)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 795.2815 419.8032 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 503.1492 407.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6533 407.8032 Tm
[(Ov)10(arian canc)15(er)]TJ
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 587.9332 407.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 520.1571 395.8032 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.6612 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 395.8032 Tm
(2)Tj
ET
EMC
/P <>BDC
BT
6 0 0 6 534.7233 399.0031 Tm
.012 Tc
(nd)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 542.5472 395.8032 Tm
.0071 Tc
.0679 Tw
[( or lat)14.9(er line aft)14.9(er r)21.9(ecurr)21.9(enc)14.9(e or f)14.9(ailur)21.9(e on platinum-based ther)24.9(ap)20.9(y within)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 914.175 395.8032 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 917.925 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 921.675 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 925.425 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 929.175 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 932.925 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 936.675 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 940.425 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 944.175 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 947.925 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 951.675 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 955.425 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 959.175 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 962.925 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 966.675 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 970.425 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 974.175 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 977.925 395.8032 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6612 383.8032 Tm
(6 months)Tj
ET
EMC
/Artifact <>BDC
.066 .001 0 0 k
486.142 120.937 209.763 158.74 re
f
EMC
/P <>BDC
BT
/F2 1 Tf
10 0 0 10 503.1492 254.6693 Tm
1 .89 0 0 k
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 511.6533 254.6693 Tm
[(K)30(e)15(y eligibility crit)15(eria)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 620.2334 254.6693 Tm
( )Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 520.1571 242.6693 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.7111 242.6693 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 242.6693 Tm
.005 Tc
.4605 Tw
[(Measur)25(able disease as per)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 673.178 242.6693 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 230.6693 Tm
-.005 Tc
-.0161 Tw
[(RECIS)15(T 1.)50(1 \(mCRPC: a dened)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 673.1782 230.6693 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 218.6693 Tm
-.0052 Tc
.0234 Tw
(number of patients with non-)Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 206.6693 Tm
-.005 Tc
0 Tw
[(measur)25(able disease allo)22(w)22(ed\))]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 669.8621 206.6693 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 520.1571 194.6693 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.7111 194.6693 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 194.6693 Tm
.005 Tc
.3002 Tw
[(A)21(c)15(c)15(e)0(s)10(sible tumor tis)10(sue f)10(o)0(r)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 673.1782 194.6693 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 182.6693 Tm
-.005 Tc
[(biops)12(y)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 561.4613 182.6693 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 520.1571 170.6693 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.7111 170.6693 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 170.6693 Tm
-.005 Tc
[(EC)20(OG PS 0-)30(1)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 591.9214 170.6693 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 520.1571 158.6693 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.7111 158.6693 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 158.6693 Tm
-.0053 Tc
.0003 Tw
[(A)20.7(dequat)14.7(e)-.3( or)20.7(gan function)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 651.9319 158.6693 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 520.1571 146.6693 Tm
()Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 525.7111 146.6693 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 528.6609 146.6693 Tm
-.005 Tc
[(No prior IL)40(-2 or IL)40(-)30(15 ther)25(ap)21(y)]TJ
ET
EMC
/Artifact <>BDC
1 .964 .92 rg
729.921 101.094 201.26 53.859 re
f
EMC
/Figure <>BDC
Q
.664 .008 0 0 k
/GS1 gs
1 i
q 1 0 0 1 830.55 156.89 cm 0 0 m
14.173 14.173 l
7.0866 14.173 l
7.0866 28.347 l
-7.0866 28.347 l
-7.0866 14.173 l
-14.173 14.173 l
0 0 l
f
Q
q
815.17 185.722 30.75 -29.539 re
845.92 185.722 m
W n
1 .89 0 0 K
0 J 0 j 1 w 10 M [] 0 d
q 1 0 0 1 830.55 156.89 cm 0 0 m
14.173 14.173 l
7.0866 14.173 l
7.0866 28.347 l
-7.0866 28.347 l
-7.0866 14.173 l
-14.173 14.173 l
0 0 l
s
Q
EMC
/P <>BDC
Q
q
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
BT
/F2 1 Tf
10 0 0 10 779.4408 129.945 Tm
1 .89 0 0 k
0 Tc
0 Tw
[(Disease pr)15(ogr)15(es)10(sion )]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 884.6611 129.945 Tm
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 768.9708 117.945 Tm
[(or unac)15(c)15(eptable t)15(o)15(xicity)]TJ
ET
EMC
/Artifact <>BDC
.048 0 .064 0 k
q 1 0 0 1 830.551 278.677 cm 0 0 m
82.622 0 l
92.015 0 99.63 -7.6147 99.63 -17.008 c
99.63 -71.701 l
99.63 -81.094 92.015 -88.709 82.622 -88.709 c
-82.622 -88.709 l
-92.015 -88.709 -99.63 -81.094 -99.63 -71.701 c
-99.63 -17.008 l
-99.63 -7.6147 -92.015 0 -82.622 0 c
h
f*
Q
EMC
/Artifact <>BDC
Q
q
830.551 279.677 m
913.173 279.677 l
923.118 279.677 931.181 271.615 931.181 261.669 c
931.181 206.976 l
931.181 197.03 923.118 188.968 913.173 188.968 c
747.929 188.968 l
737.983 188.968 729.921 197.03 729.921 206.976 c
729.921 261.669 l
729.921 271.615 737.983 279.677 747.929 279.677 c
W* n
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
1 .89 0 0 K
0 J 0 j 2 w 10 M [] 0 d
q 1 0 0 1 830.551 279.677 cm 0 0 m
82.622 0 l
92.567 0 100.63 -8.0624 100.63 -18.008 c
100.63 -72.701 l
100.63 -82.646 92.567 -90.709 82.622 -90.709 c
-82.622 -90.709 l
-92.568 -90.709 -100.63 -82.646 -100.63 -72.701 c
-100.63 -18.008 l
-100.63 -8.0624 -92.568 0 -82.622 0 c
s
Q
EMC
/P <>BDC
Q
q
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
BT
/F2 1 Tf
10 0 0 10 789.211 254.6693 Tm
1 .89 0 0 k
-.0007 Tc
.0007 Tw
[(Study tr)14.3(eatment)]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 871.891 254.6693 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 760.8383 242.6693 Tm
-.0055 Tc
.0005 Tw
[(SO)47.5(T101 12 )]TJ
ET
EMC
/P <>BDC
BT
/TT2 1 Tf
10 0 0 10 811.0685 242.6693 Tm
0 Tc
0 Tw
()Tj
ET
EMC
/P <>BDC
BT
/F1 1 Tf
10 0 0 10 817.2833 242.6693 Tm
-.005 Tc
[(g/k)21(g s.)20(c. on da)17(y)17(s)0( )]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 903.1636 242.6693 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 761.3356 230.6693 Tm
-.0052 Tc
.0002 Tw
[(1, 2, 8, 9 in c)14.8(ombination with )]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 902.6665 230.6693 Tm
0 Tc
0 Tw
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 763.6357 218.6693 Tm
-.005 Tc
[(pembr)22(olizumab i.)85(v)85(.)0( 200 mg )]TJ
ET
EMC
/P <>BDC
BT
10 0 0 10 900.3663 218.6693 Tm
0 Tc
( )Tj
ET
EMC
/P <>BDC
BT
10 0 0 10 774.3706 206.6693 Tm
-.005 Tc
[(on da)17(y 1 e)24(v)27(ery 3 w)22(eeks)]TJ
ET
EMC
/Figure <>BDC
Q
q
17.196 410.355 457.762 -286.379 re
W n
12.756 417.401 462.047 -300.472 re
886.681 206.669 m
W* n
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
q
457.762 0 0 286.379 17.196 123.976 cm
/Im2 Do
Q
EMC
/Figure <>BDC
Q
q
699.136 249.703 29.554 -30.761 re
W n
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
q 1 0 0 1 727.983 234.322 cm 0 0 m
-14.173 14.173 l
-14.173 7.0866 l
-28.347 7.0866 l
-28.347 -7.0866 l
-14.173 -7.0866 l
-14.173 -14.173 l
0 0 l
f
Q
Q
q
699.151 249.692 29.539 -30.75 re
W n
699.136 249.703 29.554 -30.761 re
W n
0 797.244 1417.323 -797.244 re
708.66 398.64 m
W n
0 797.25 1417.32 -797.25 re
W n
1 .89 0 0 K
0 J 0 j 1 w 10 M [] 0 d
q 1 0 0 1 727.983 234.322 cm 0 0 m
-14.173 14.173 l
-14.173 7.0866 l
-28.347 7.0866 l
-28.347 -7.0866 l
-14.173 -7.0866 l
-14.173 -14.173 l
0 0 l
s
Q
EMC
Q
endstream
endobj
16 0 obj
<<
/ExtGState <<
/GS1 21 0 R
>>
/Font <<
/F1 22 0 R
/F2 23 0 R
/F3 24 0 R
/TT1 25 0 R
/TT2 26 0 R
/TT3 27 0 R
>>
/ProcSet [/PDF /Text /ImageC]
/XObject <<
/Im1 28 0 R
/Im2 29 0 R
>>
>>
endobj
17 0 obj
<<
/K [30 0 R 31 0 R 32 0 R 33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R
46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R
62 0 R 63 0 R 64 0 R]
/P 11 0 R
/S /Article
>>
endobj
18 0 obj
[30 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R 65 0 R
65 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 66 0 R 67 0 R
67 0 R 67 0 R 67 0 R 67 0 R 67 0 R 67 0 R 67 0 R 67 0 R 67 0 R 67 0 R 67 0 R 68 0 R 69 0 R 69 0 R 69 0 R 69 0 R
69 0 R 69 0 R 69 0 R 69 0 R 70 0 R 70 0 R 70 0 R 70 0 R 70 0 R 71 0 R 71 0 R 71 0 R 71 0 R 71 0 R 71 0 R 71 0 R
72 0 R 72 0 R 72 0 R 72 0 R 72 0 R 72 0 R 72 0 R 72 0 R 72 0 R 72 0 R 73 0 R 73 0 R 73 0 R 73 0 R 73 0 R 74 0 R
74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R
74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 74 0 R 75 0 R 75 0 R 75 0 R 75 0 R 75 0 R 76 0 R 77 0 R
77 0 R 77 0 R 77 0 R 78 0 R 78 0 R 78 0 R 79 0 R 79 0 R 79 0 R 80 0 R 80 0 R 80 0 R 80 0 R 80 0 R 80 0 R 81 0 R
82 0 R 82 0 R 83 0 R 84 0 R 85 0 R 85 0 R 85 0 R 85 0 R 85 0 R 85 0 R 86 0 R 86 0 R 86 0 R 86 0 R 86 0 R 87 0 R
87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R 87 0 R
87 0 R 87 0 R 88 0 R 88 0 R 88 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R
89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R 89 0 R
89 0 R 90 0 R 90 0 R 90 0 R 91 0 R 91 0 R 91 0 R 91 0 R 92 0 R 92 0 R 92 0 R 93 0 R 93 0 R 94 0 R 95 0 R 95 0 R
95 0 R 95 0 R 95 0 R 96 0 R 96 0 R 96 0 R 97 0 R 97 0 R 97 0 R 97 0 R 98 0 R 98 0 R 98 0 R 98 0 R 99 0 R 99 0 R
99 0 R 99 0 R 99 0 R 99 0 R 100 0 R 100 0 R 100 0 R 100 0 R 100 0 R 100 0 R 100 0 R 100 0 R 101 0 R 101 0 R 101 0 R 102 0 R
102 0 R 103 0 R 104 0 R 104 0 R 104 0 R 104 0 R 104 0 R 104 0 R 104 0 R 104 0 R 104 0 R 105 0 R 105 0 R 106 0 R 107 0 R 107 0 R
107 0 R 107 0 R 107 0 R 107 0 R 107 0 R null null null null null null null 107 0 R 107 0 R 107 0 R 108 0 R
109 0 R 109 0 R 109 0 R 109 0 R 109 0 R 109 0 R 109 0 R 109 0 R 109 0 R 110 0 R 110 0 R 110 0 R 110 0 R 110 0 R 110 0 R 110 0 R
110 0 R 110 0 R 110 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R
111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R
111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 111 0 R 112 0 R 113 0 R 114 0 R 114 0 R 115 0 R 116 0 R 116 0 R 117 0 R
56 0 R 118 0 R 119 0 R 119 0 R 119 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R
120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 120 0 R 121 0 R 121 0 R 121 0 R 122 0 R 122 0 R 122 0 R 122 0 R 122 0 R
122 0 R 123 0 R 123 0 R 123 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R
124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 124 0 R 125 0 R 125 0 R 125 0 R 126 0 R 126 0 R
126 0 R 126 0 R 126 0 R 126 0 R 127 0 R 127 0 R 127 0 R 128 0 R 128 0 R 128 0 R 128 0 R 128 0 R 128 0 R 129 0 R 129 0 R 129 0 R
130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R
130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 130 0 R 131 0 R 131 0 R 131 0 R 132 0 R 132 0 R 132 0 R 132 0 R 132 0 R
132 0 R 132 0 R 132 0 R 132 0 R 133 0 R 133 0 R 133 0 R 133 0 R 133 0 R 133 0 R 134 0 R 134 0 R 134 0 R 134 0 R 135 0 R 135 0 R
135 0 R 135 0 R 136 0 R 136 0 R 136 0 R 60 0 R 137 0 R 137 0 R 138 0 R 139 0 R 139 0 R 140 0 R 140 0 R 140 0 R 140 0 R 141 0 R
141 0 R 142 0 R 142 0 R 143 0 R 63 0 R 64 0 R]
endobj
19 0 obj
<<
/P [144 0 R]
/Fi [145 0 R]
>>
endobj
20 0 obj
<<
/Me 146 0 R
>>
endobj
21 0 obj
<<
/AIS false
/BG2 /Default
/BM /Normal
/ca 1
/CA 1
/OP false
/op false
/OPM 1
/SA false
/SM 0.02
/SMask /None
/TK true
/Type /ExtGState
/UCR2 /Default
>>
endobj
22 0 obj
<<
/BaseFont /BBKHFB+GothamRounded-Book
/Encoding 147 0 R
/FirstChar 2
/FontDescriptor 148 0 R
/LastChar 239
/Subtype /Type1
/ToUnicode 149 0 R
/Type /Font
/Widths [735 998 500 500 500 500 500 500 500 500 500 500 500 500 500 500
500 500 500 500 500 500 500 500 500 500 500 500 500 500 300 500
500 500 500 834 696 500 434 434 430 625 245 408 245 508 715 358
599 613 671 612 647 596 630 647 255 255 500 500 500 500 500 784
722 738 782 670 656 784 760 291 553 714 619 868 790 850 668 500
723 640 648 759 500 1101 500 500 500 439 500 439 500 500 500 579
664 571 664 592 367 664 616 263 263 568 263 951 616 646 664 664
405 498 404 616 584 858 571 587 556 500 500 500 500 500 478 500
500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
500 631 500 500 500 500 500 500 500 500 500 500 500 500 500 500
500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
500 500 500 500 500 500 500 500 500 500 500 500 500 263]
>>
endobj
23 0 obj
<<
/BaseFont /BBKHFD+GothamRounded-Bold
/Encoding 150 0 R
/FirstChar 2
/FontDescriptor 151 0 R
/LastChar 128
/Subtype /Type1
/ToUnicode 152 0 R
/Type /Font
/Widths [1066 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
500 500 500 500 500 500 500 500 500 500 500 500 500 500 300 500
500 500 500 500 500 286 500 500 500 500 286 408 286 500 730 422
623 621 689 630 662 619 500 500 296 296 500 500 500 500 500 766
722 738 782 670 656 784 760 336 564 712 619 868 790 850 668 500
723 640 648 756 726 500 500 500 500 500 500 500 500 500 500 592
675 571 675 613 382 675 623 302 302 588 302 950 623 664 675 500
418 502 415 623 588 849 574 586 563 500 500 500 500 500 500]
>>
endobj
24 0 obj
<<
/BaseFont /BBKHHG+GothamRounded-BookItalic
/Encoding 153 0 R
/FirstChar 32
/FontDescriptor 154 0 R
/LastChar 116
/Subtype /Type1
/ToUnicode 155 0 R
/Type /Font
/Widths [300 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
715 500 595 500 500 500 500 500 500 500 500 500 500 500 500 500
500 747 500 735 773 500 500 500 500 500 500 500 500 500 500 842
500 500 500 637 500 500 500 500 500 500 500 439 500 439 500 500
500 576 500 500 659 589 500 500 500 500 500 500 500 500 613 500
659 500 402 496 401]
>>
endobj
25 0 obj
<<
/BaseFont /BBKHFC+LucidaGrande
/DescendantFonts [156 0 R]
/Encoding /Identity-H
/Subtype /Type0
/ToUnicode 157 0 R
/Type /Font
>>
endobj
26 0 obj
<<
/BaseFont /BBKHHF+LucidaGrande
/Encoding /WinAnsiEncoding
/FirstChar 181
/FontDescriptor 158 0 R
/LastChar 181
/Subtype /TrueType
/Type /Font
/Widths [626]
>>
endobj
27 0 obj
<<
/BaseFont /BBKHFA+Noteworthy-Light
/DescendantFonts [159 0 R]
/Encoding /Identity-H
/Subtype /Type0
/ToUnicode 160 0 R
/Type /Font
>>
endobj
28 0 obj
<<
/BitsPerComponent 8
/ColorSpace /DeviceRGB
/Filter /FlateDecode
/Height 234
/Length 3634
/Subtype /Image
/Type /XObject
/Width 234
>>
stream
HAnGO' kr=Zd+UCI-o]M|5,Y05qfYZÒ;sYge]M|5,Y05qfYZÒ;sYge]M|5,Y05qfYZÒiY;3][ sYx.魄Ͽb,a[Y:eY<[b!˲x,x\ Yc,cezOȜ5r<9 anC+Z#Ǔc6AȜ5r<9 anC+Z#Ǔc6AȜ5r<9 anC+Z#Ǔc6AlYe5=ق9,'zkz>asfYO&|f̲,\/M̙eY>^֛\ -3˲|r7e2ՔZc̲,Ba2YkYEȜs>LVS&k]B3˲s·jdKvfY!s0YM5v ,"d9&)ikLZ7[ozOxߜ'ozOxߜ'ozOxߜ'jbUB_K.}؛\a7W 5-,aojZrYCl
K9\,e9Oos-,,kbVɥ[YlC+ò>L9IiVSƓB+5=jxrAhe3[MO;,|f)uŚl5e< X'"de|5IgLgr>ʚ3Bbn
sY9leMc17نs&ⱘl\V·9[YtFhXta.+ÜI:#x,\ʲv[Xov5Y)GZXYnͮ&1Y+˺mad1!kaeYW-7,Ɣ#d-,jfWŘre]*\'eʵh^5},OsCkѼjXλ,+עyw'>
YVEc9O|\UrM47dYͫO0l0fM)bYwr0fM)bYwr0fM)bYwr0fM)bYwr0fM)bYwr0fM)b'>"-岬&VfSveZ̖rYb}X{)-fK,k>սٔ]Y\dlʮ,BR.Zlkauo6eWl)e-6هhvZX^Mܪ̙1"cz5s2g|Ztέʜi-r>VzW9*sf̧X^Mܪ̙1"cz5s2gz7MgdXٺ131]gdXٺ131]gdXٺ131]gdXٺ131]gdXٺ131]gdXٺ1[<3kwy,,Xor]K,bf>s3}˲)LIJ,fca17wy,,Xor]K,bLsW95Io:sn>qeMқά*[#cOsY3>9X\$̺Orι5r>V95Io:sn>qeMқά*[#w>Z,:/2]1Be5eM[2]1Be5eM[2]1Be5eM[2]1Be5eM[2]1Be5eM[2]1\Uns93mOsܼbLka973zZX+s93mwܼbLk6XW976YM"XW976YM"XW976YM"XW976YM"XW976YM"XW976Yue9瘟oiMsY3Ӯssg&|Z\̴ܙ94e93:7wfbΧ5eYL͝iMsY3Ӯssg&|Z\t"d,=҄bfkX>>&3s_u4!uuO ̜װ|}r-M-fl]cniBh13fzNV/+ZW9·.k
[ϵ`}UZžqC*Gs-b߸u#|loкj2r~kIiu\1&-&Y)}r|؛\wd\aorbur'ẆuGIiu\1&-&Y~r>̙aJ?M5b̙aJ?M5b̙aJ?M5b̙aJ?M5b̙aJ?M5b̙aӹ#dMsY+72?LZ4el)GhF盉X-7|3kєo&b-v#|#DESΖr֛od~(םEgc]Ybtce5OLx+[,|fss uebҙ>qn3ᱮ^l\:'}&<֕Ջ-Kg>VVĹτǺzrbzZXrb[o++F8ijZXrb[o++F8ijZXrb[o++F8i|MSc2fS9)sMsŔeX̹rbx,\Slj9z1zY<a)sn6sr,0ה97,kK܆MBòO.Lm$d>,XzN܆MBòO.Lm$d>,XzN܆MBòO.Lm$d>Mi/o&b>Vz34yo&b>Vz34yo&b>Vz34yo&b>Vz34yo&b>Vz34yo&b>/;cgFp3sd'l$2flZcO9I:#dْƧJ85rtFȘ%kO7>qfk'錐13gKn+}NaO +Or
endstream
endobj
29 0 obj
<<
/BitsPerComponent 8
/ColorSpace /DeviceRGB
/Filter /FlateDecode
/Height 645
/Length 382442
/Subtype /Image
/Type /XObject
/Width 1031
>>
stream
HKlWE(1Aad)C[`fJ[
!(ԉ5iy8adx0hy
&e֑b#__+}NE78gYg,@ @ @ @ @ @ @ @ @ @ @ @ x_qwOW
=cfVW3N^7S{ws̼ػq^F=LWmmiYqO?}1c<̝;i`` sݻ~a`
ŌߖM6$>[$qZIVr_*$[WW֭[v Xx~+V$?9yK⭷,!Po۶?
AH'cǎ%b¸¬0|FR7=U,Y.l!\x.<:Dړ1ߐwyK{FGʆGI/њJW
v(&¾}yBfrH(X&IW.[GMMMIj!iY-5]Q(OYdczT^&"h
سgՕ9%x&,tmo&atdkmIBYBU9'a{d!OzVW61W}JBO(`wK(GݻucGTM6%o>\%
I0P,!
Z_V)SHAFfY
Uh
7Sd.|Qҹ؆0*{ҥ:@ /)පB/_4yJ~+[Db1 KD!,_V(ZƷ+VP0>!:5}YqԩS\pNW ܿ?R(|C:+W^z饊
.\rTg6+__ɚsfϟk.-LVo!*++o6-ĭkllHƍov>;v06mZ[[S{bꫯ9swܹxbV/H&:7o2)3sڵuɁk'K8pҥK[8q"nϞ=[g@ŋmOENC>pUD_
=ۄMss3~wy$f̘A
iX~ΝJ9do9g^/lܸ֭[|ʽ?k5ئ_|嗼?6c ;.YKv&>KŖx@I'7b6f#.>[al$A{{;_>}m۶eN DLRG#1ɆhBxTٳ*h+'NX`܀pUcJb[^95"wI~G24BMn;a)C)3Edݙkx-- ӧO'>䯿D7o]}O1C0OPYB0I0!rT&qC}DZau%[Ø
Q֟f|aɓQدYEH=OlݺfV]@À/b^+>Cޢ9r䈤Osؾ}f6l@b$GAV~ra&Eqس K8Of8su%|-+Xb|-[ln΄-R &Y+W_}E iY){c4I*\Rޓ=Y;/|u$
cBmUayV3TL,O3g΄v] nIvna9Oc3g5OX2F677CQ&-` &K{#3V:`-kd 3r+*fT$,*B &@h gVbf֬Y$f&˺<^|E`BCCg%1WTVVJ̰UVj
T&P